IN0V8
Posted - 1 week ago
$IRON Watch / Opportunity H.C. Wainwright raises target price to $118 from $70
T1T00
Posted - 2 weeks ago
$IREN You all laughed but the prophecy has come true. 🙏
BOTH BTDR & HUT have now outperformed IREN
But today’s HUT news makes me bullish for IREN & RIOT I will be slowly increasing both $IRON & $RIOT after FOMC
S_Franconi
Posted - 2 weeks ago
$IRON Thank you $IRON. Great day.
justiceforb_85
Posted - 2 weeks ago
$IRON great data for DISC-0974 in myelofibrosis and anemia. This company has a bright future.
TruthTooPower
Posted - 2 weeks ago
$IRON !!!
This Beast Will Blow through HOY!!! $100+ in the Batters Box!!!!
FramusMorgan
Posted - 1 month ago
📈 Stock Performance for $IRON over the Last Month:
Opening Price: $46.85
Closing Price: $64.96
Highest Price: $68.73
Lowest Price: $44.81
Emma_King
Posted - 1 month ago
💥 Huge news expected for MYNZ soon 💥 Nov 12: 51M volume, +28%, with 19M short volume. With everyone awaiting the meeting results, I have a strong feeling the r/s extension will be pushed out another 180 days. Mainz Biomed (MYNZ) has partnered with Thermo Fisher (TMO, $209.2B market cap, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B revenue and advanced tech will boost MYNZ’s mRNA-based assays, achieving 85% detection for advanced adenomas, compared to competitors' 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Sentiment: Positive 1. Strategic partnership with industry giant Thermo Fisher 2. Access to Thermo Fisher's advanced tech 3. Potential for global commercialization 4. Development of home collection screening capability Win-win as TMO steps into the CRC market, too. Calling all apes, let’s crush the short sellers—this bull run is ours. $TNYA $IRON
IN0V8
Posted - 1 month ago
$IRON Opportunity| H.C. Wainwright raises target price to $118 from $70
justiceforb_85
Posted - 1 month ago
$IRON data for bitopertin is good. DISC-0974 would be a game-changer for anemia of chronic disease.
StockBraker
Posted - 1 month ago
$IRON Disc Medicine (IRON) reported a Q3 loss Tuesday of $0.89 per share, wider than a loss of $0.58 a year earlier. Analysts polled by Capital IQ expected a loss of $0.99. As expected, no revenue for the quarter ended Sept. 30 was reported. As of Sept. 30, the company had $487.4 million in cash, cash equivalents and market
S_Franconi
Posted - 1 month ago
$IRON
StockBraker
Posted - 1 month ago
$IRON Disc Medicine has obtained a $200 mln non-dilutive term loan facility from Hercules Capital, Inc. (HTGC) Facility significantly increases future financial and operational flexibility. Up to $200 mln available, with $30 mln drawn at close and additional $80 million available at Disc''s sole discretion through second-half 2026. Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP.
Thestocktraderhubzee
Posted - 1 month ago
WATCHLIST NOV 06 2024
$IRON Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $70
$GFS Citigroup Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $40
$NSSC Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41
$SNAP Loop Capital Maintains Buy on Snap, Raises Price Target to $16
$FBRT Jones Trading Maintains Buy on Franklin BSP Realty Trust, Maintains $15 Price Target
ChartLaboratory_com
Posted - 1 month ago
🚀 $VRNA climbs +9.06%! Targeting $39.38 resistance! 📈 www.patreon.com/chartlab 📈 $RYTM is up +8.12%! Watch for break above $55.64! 🔥 www.patreon.com/chartlab 📊 $FUTU steady at +1.91%! Key support at $94.29! Don't miss out! 🌟 www.patreon.com/chartlab 📈 $IRON soars +23.59%! Look for $62.26 target! 🚀 www.patreon.com/chartlab Stay updated with the latest trading insights and strategies! 🌟 www.patreon.com/chartlab ChartLAB Daily: www.patreon.com/chartlab The Best & Trusted Source for Quality Trading Education! Join our community 🔑 Unlock the best trade plan education 📬 exclusive news 📊 in-depth analysis 📡 actionable trades delivered to you every day ChartLAB = realtime success Expert insights and timely alerts Empower your trading decisions Why Subscribe? Smart Strategies & Education Exclusive Premium Benefits & Newsletter Join today! www.patreon.com/chartlab #StocksToBuy #TradingTips #StockMarket #SwingTrade #Education #Alerts
IN0V8
Posted - 1 month ago
$IRON Opportunity Leerink Partners raises target price to $85 from $65 Raymond James raises target price to $110 from $66 Raymond James raises to strong buy from outperform
Bornjever
Posted - 1 month ago
$ATSG $IART $IRON so what are 3 biggest stock news outlets??? This was really good company in 2022 like over 12.00 per share. Am talking about MYNZ of course.
StockBraker
Posted - 1 month ago
$IRON Consensus currently at $85 with Morgan Stanley upgrade. BMO and Raymond James at high end with $111 avg. Several here are alumni of the Gemini Therapeutics reverse merger and likely thrilled to finally see some recovery. For ref - https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-completion-merger-gemini-therapeutics
DonCorleone77
Posted - 1 month ago
$IRON Disc Medicine upgraded to Overweight from Equal Weight at Morgan Stanley Morgan Stanley upgraded Disc Medicine to Overweight from Equal Weight with a price target of $85, up from $40. With the company's end-of-Phase 2 meeting feedback indicating potential for accelerated approval based on existing data, the firm contends that bitopertin is likely to reach the market faster and with a higher probability, the analyst tells investors in a research note. If Disc is able to secure accelerated approval of bitopertin, aspects of the firm's bull case begin to come into play, with shares having potential to top $110, the firm added.
THESTOCKWATCHGURU
Posted - 1 month ago
$SPY $QQQ $IRON $IRON is currently up 26% after announcing positive feedback from its end-of-Phase 2 meeting with FDA, supporting the regulatory path forward for Bitopertin in EPP. Keep an eye out of this stock people.
jParkz
Posted - 1 month ago
$IRON News Article Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval https://marketwirenews.com/news-releases/disc-medicine-announces-successful-end-of-phase-2-me-6593951196821206.html $IRON
thetechtrader
Posted - 1 month ago
$IRON popped to 51, spiked to 56 +9, tagged 60 +13.75. Extension targets are 61 & 64+ Support 56 & 54. #technicaltrading #daytrade #tradealert #marketrecap #stockstowatch #stockstobuy
S_Franconi
Posted - 1 month ago
$VRNA Another great day here. $VRNA $IRON $EWTX $IMTX $AVBP
Donniechen12345
Posted - 1 month ago
$IRON shorted more here another 1.5 k shares at 57.10…. eod easy 54-55… reading thisnlike a book haha . this pig will fall :))$$$$$$
iamwhatspoppin
Posted - 1 month ago
$IRON
Donniechen12345
Posted - 1 month ago
$IRON shorted this pig st $59.01 4 k shares and NOT looking back essy $$$$ hahaha thx rookies!!!! lol
StockBraker
Posted - 1 month ago
$IRON has been upgraded by Raymond James as a strong buy at $110
MaverikIT
Posted - 1 month ago
@IsabellaDC @net0trader $IRON a day keeping yout out of hospital. $THC +5.74 $HCA - love these 2 though
MaverikIT
Posted - 1 month ago
@IsabellaDC @net0trader @RonIsWrong $IRON - getting your vitamin$ for today ? $VKTX $TGTX - bummer
G101SPM
Posted - 1 month ago
$IRON $59.45 +12.32. SPM 87.95 to $110.00 in midterm. Disc Medicine announces "positive" feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, supporting the regulatory path forward for bitopertin in EPP (47.13) Alignment with the FDA across all proposed study parameters, providing a clear development path to registration. Agreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment period. Potential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpoint. Plan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025.